The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner
Authors
Keywords
-
Journal
Pigment Cell & Melanoma Research
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-05-07
DOI
10.1111/pcmr.12788
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade
- (2019) Neda Nikbakht et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
- (2018) Hatice Gulcin Ozer et al. Cancer Discovery
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
- (2017) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
- (2017) Barbara Fontanals-Cirera et al. MOLECULAR CELL
- Cyclooxygenase 2: protein-protein interactions and posttranslational modifications
- (2017) Anna Alexanian et al. PHYSIOLOGICAL GENOMICS
- Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer
- (2017) Dennis O. Adeegbe et al. Cancer Discovery
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
- (2016) S Bowyer et al. BRITISH JOURNAL OF CANCER
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
- (2016) Francisco Aya et al. Future Oncology
- BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
- (2016) Yuki Kagoya et al. JOURNAL OF CLINICAL INVESTIGATION
- Ipilimumab in anti-PD1 refractory metastatic melanoma
- (2016) Aurélie Jacobsoone-Ulrich et al. MELANOMA RESEARCH
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
- (2016) Katrina Meeth et al. Pigment Cell & Melanoma Research
- Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice
- (2016) Dong U. Lee et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
- (2016) Luca Paoluzzi et al. Cancer Medicine
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation
- (2015) Patricia A. Toniolo et al. JOURNAL OF IMMUNOLOGY
- Targeting BET bromodomains for cancer treatment
- (2015) Marie Jung et al. Epigenomics
- Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
- (2015) Stuart Gallagher et al. Cancers
- The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts
- (2014) Kerstin Klein et al. ANNALS OF THE RHEUMATIC DISEASES
- The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
- (2014) Stuart J. Gallagher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Multiple murine BRafV600Emelanoma cell lines with sensitivity to PLX4032
- (2014) Molly H. Jenkins et al. Pigment Cell & Melanoma Research
- Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
- (2014) Stuart J. Gallagher et al. Pigment Cell & Melanoma Research
- Brd4 is on the move during inflammation
- (2014) Yali Xu et al. TRENDS IN CELL BIOLOGY
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- HMGB1 in Cancer: Good, Bad, or Both?
- (2013) R. Kang et al. CLINICAL CANCER RESEARCH
- Regulation of Immune Responses by Prostaglandin E2
- (2011) P. Kalinski JOURNAL OF IMMUNOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started